Italy: Medical and Donor Requirements for Assisted Reproduction
The short answer
Italy’s rules distinguish medically assisted reproduction (PMA), including treatment with donated sperm or eggs, from surrogacy. Donor gametes may be used within the legal framework and after medical screening; they do not make a surrogacy arrangement lawful in Italy. The decision turns on the intended treatment, the applicants’ status, the documented medical indication, donor safety checks and the authorisation of the clinic. The statutory baseline is national, but the clinic’s medical protocol and regional service or funding rules may add operational conditions. Ask the provider to identify the legal or clinical basis for each restriction rather than treating every clinic rule as a national statutory requirement.
Italian law permits heterologous PMA—using sperm or eggs from a donor—in qualifying cases. The Constitutional Court removed the absolute statutory ban in 2014 for eligible couples with diagnosed absolute and irreversible sterility or infertility. The treatment must still comply with the separate rules on who may access PMA, medical indication, consent, donor selection and authorised facilities. This is not a general right to any treatment, nor a route to surrogacy.
Which rules control?
The starting point is Law 40/2004, read together with binding Constitutional Court judgments, the technical donor-screening rules in Presidential Decree no. 131/2019, and the Ministry of Health’s PMA guidelines of 20 March 2024. The National Transplant Centre and the ISS National PMA Register provide official operational information. These sources do different jobs: legislation sets the framework, court judgments remove or clarify statutory limits, technical rules govern safety, and official guidance explains implementation. A clinic’s own policy is not automatically equivalent to a statute or regulation.
Who may access PMA in Italy?
Article 5 of Law 40/2004 describes eligible applicants as adults of different sexes who are married or cohabiting, are both alive and are of potentially fertile age. The Constitutional Court upheld the different-sex-couple restriction in judgment no. 221/2019. A single person, a same-sex couple or a couple that does not meet the statutory relationship requirements should not assume that a clinic can lawfully accept the request. Article 5 does not itself set one numerical upper age for every recipient: the medical assessment, the type of service and regional funding rules must be checked separately. In judgment no. 69/2025, the Constitutional Court rejected a challenge to Article 5’s exclusion of single women; that ruling did not open PMA access to single applicants.
What medical indication is required?
PMA is generally framed as a response to documented sterility or infertility when the cause cannot otherwise be removed effectively. A clinician should record the diagnosis and explain why the proposed technique is medically indicated. The statutory principle of graduality favours the least invasive effective option, rather than automatically starting with the most complex procedure. There is a separate constitutional exception for certain fertile couples carrying serious transmissible genetic diseases: access with preimplantation diagnosis may be possible when the disease meets the legal severity criteria and is confirmed by an appropriate public specialist structure. That exception is not a blanket rule for every genetic risk or every donor-gamete request.
When may donor sperm or eggs be used?
Heterologous PMA is not prohibited in itself. Under judgment no. 162/2014, the absolute ban could not be applied to an eligible couple where a medical condition causes absolute and irreversible sterility or infertility. The responsible clinician must identify the clinical indication; a preference for a donor, without the required legal and medical basis, should not be assumed sufficient. Gamete donation is voluntary and unpaid. The statutory prohibition on commercialising gametes is distinct from a lawful, screened donation through the regulated system. Donor-gamete treatment does not authorise an embryo to be carried by a third-party surrogate.
Binding donor age and numerical limits
The national technical rules allow gamete donation by men aged 18–40 and women aged 20–35. Gametes from one donor must not result in more than ten births. The regulation provides a narrow exception where a couple that already had a child through heterologous PMA seeks another treatment using gametes from the same donor. An egg donor may undergo no more than six ovarian-stimulation cycles. These are regulatory baselines, not merely informal clinic preferences; ask the centre to explain how it records donor use and applies the limits.
Required donor screening
Donor selection is based on medical and family history, a questionnaire and an individual interview with the responsible clinician or appropriately trained staff. Required infectious-disease testing includes HIV 1 and 2, hepatitis C, hepatitis B and syphilis; sperm donors must also test negative for chlamydia using a nucleic-acid amplification test on a urine sample. HTLV-I testing is required in specified higher-risk circumstances, including relevant residence, origin or partner/family links. A medical-genetics consultation, written assessment and cystic-fibrosis test are required for genetic screening, with further tests—including a karyotype—where indicated by the assessment. The rules allow additional tests based on the donor’s history and the donated cells.
Quarantine, repeat testing and residual risk
For gametes donated by someone other than the recipient’s partner, blood samples are taken at donation; for donated eggs, the start of stimulation may be treated as the donation date. The general rule is quarantine for at least 180 days followed by repeat tests. No quarantine is required if the donation-time blood sample also undergoes NAT testing for HIV, HBV and HCV, in addition to serological tests. Repeat testing is also not required if the treatment includes a validated inactivation step for the relevant viruses. Donor test results must be available before use. Screening reduces risk but cannot guarantee that no infection or inherited condition will affect a child.
Check the clinic and the donor pathway
Use a centre authorised under the Italian regional system and check its entry in the National PMA Register or the official centre listings. The register helps verify that the facility is authorised; it does not guarantee that every centre offers every donor treatment. The National Transplant Centre states that centres and sperm banks may collect donated gametes under the selection criteria, although not all are operationally organised to do so. Ask whether gametes are sourced domestically or imported, which bank supplied them, how traceability is maintained, and which tests and release conditions were documented before the gametes were used.
Consent and information for the intended parents
Before treatment, the applicants must receive information about the available technique, its risks and the relevant legal consequences, and consent must be recorded in the form required by law. In heterologous treatment, the couple must receive detailed information about the donor’s clinical tests, the risk-reduction measures and the fact that testing cannot conclusively exclude every disease. Donor confidentiality is protected, including through indirect identification systems; do not rely on a clinic’s casual assurance of absolute anonymity or assume that all future medical-information questions have the same answer. Ask how consent, records, donor coding and later medical updates are handled.
National law versus clinic policy
The practical distinction matters because a refusal may reflect a binding legal limit, a safety rule or the clinic’s own clinical policy. Ask the clinic to name the source and the consequence for your case. A policy may be medically reasonable without being a statutory age limit; conversely, a clinic cannot waive a binding donor-screening or eligibility rule simply because a patient accepts the risk.
| Issue | Binding baseline | What to verify with the clinic |
|---|---|---|
| Applicants | Adult different-sex couple; married or cohabiting; both alive; potentially fertile age. | How the centre assesses potentially fertile age and which regional service/funding criteria apply. |
| Donor | Age ranges, history and clinical screening, specified infection tests, donor-use limits and traceability. | Any extra genetic panel, matching criteria or wait-list rule, and its medical or regional basis. |
| Treatment | Documented medical indication, authorised facility and legally valid informed consent. | Why this technique is recommended, alternatives, costs and the exact consent documents. |
Documents and answers to request in writing
Before paying a deposit or beginning stimulation, request a written intake and treatment plan. The exact paperwork varies with the clinical case and provider, but it should be possible to identify the documents supporting eligibility, the indication for heterologous PMA and the centre’s authority.
- Identity and civil-status documents requested to establish the applicants’ eligibility; confirm whether translations or formal certifications are needed.
- Medical reports documenting sterility/infertility or the relevant genetic condition, plus the clinician’s written indication for the proposed technique.
- The clinic’s authorisation/register details and the identity of the gamete bank or source, with confirmation of traceability.
- A written explanation of donor screening, test timing, quarantine or the legal basis for an exception, and any additional tests.
- Informed-consent forms, the risk explanation, the treatment plan, the price breakdown and the clinic’s written reason for any refusal or age limit.
Common failure points
Do not rely on a website statement that a clinic “offers donor eggs” without checking whether it can accept your specific applicants and medical indication. Do not confuse a clinic’s age cut-off with a single national statutory maximum, or assume that an overseas donor bank removes Italian safety requirements. A genetic panel, donor phenotype match, waiting list or funding limit may be an operational or regional condition; request its source. Conversely, do not treat donor screening as a guarantee of a healthy child, and do not proceed if the provider cannot explain the tests, traceability, consent process or authorisation.
Surrogacy remains a separate prohibition
These rules concern PMA and gamete donation; they do not make surrogacy lawful in Italy. Article 12(6) of Law 40/2004 prohibits realising, organising or publicising surrogacy, with criminal penalties. Law no. 169/2024, effective from 3 December 2024, adds that an Italian citizen is punishable under Italian law for the specified surrogacy conduct committed abroad. The application of this rule to an individual fact pattern requires separate legal advice. A clinic’s lawful use of donor sperm or eggs cannot validate a surrogacy contract or resolve parentage, birth-registration, nationality or travel issues.
A safe decision sequence
First, identify the exact treatment: partner gametes, donor gametes, embryo transfer or a proposed surrogacy arrangement are not interchangeable. Second, obtain the diagnosis and a written clinical indication. Third, confirm that the applicants meet Article 5 and ask how any exceptional case is legally supported. Fourth, verify the centre and donor pathway, screening and traceability. Fifth, review consent, residual risks, costs and any clinic-specific restrictions in writing. If the centre relies on an age limit, genetic rule, donor exception or refusal, ask for the statute, decree, national guideline, regional act or clinical-policy document. Where the answer affects surrogacy, parentage or cross-border plans, obtain separate Italian legal advice before committing money or beginning treatment.
Official sources
- [S1] Legge 19 febbraio 2004, n. 40 — testo consolidato (Normattiva)
- [S2] Corte costituzionale, sentenza n. 162/2014
- [S3] Corte costituzionale, sentenza n. 221/2019
- [S4] Corte costituzionale, sentenza n. 96/2015
- [S5] D.P.R. 23 agosto 2019, n. 131 — Gazzetta Ufficiale
- [S6] Centro Nazionale Trapianti — Donare le cellule riproduttive
- [S7] Ministero della Salute, decreto 20 marzo 2024 — Linee guida PMA
- [S8] Istituto Superiore di Sanità — Registro nazionale PMA
- [S9] Legge 4 novembre 2024, n. 169 — Gazzetta Ufficiale
- [S10] Constitutional Court, judgment no. 69/2025 (single women and access to PMA)
This page is not an approval to proceed with treatment and does not replace advice on individual facts.
